| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Studies |
Departments of Surgery (S.X., P.S., J.M.P.H.) and Medicine (S.X., J.L.B., J.S.), University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom BS2 8HW
Address all correspondence and requests for reprints to: Dr. Jeffrey M. P. Holly, Department of Surgery, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom BS2 8HW.
Proteolysis of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) is an important determinant of IGF action on cells. We have investigated this in a human skin keratinocyte cell line HaCaT. Although these cells did not normally produce an active IGFBP-3 protease, addition of plasminogen resulted in a dose-dependent proteolysis of endogenous and exogenous IGFBP-3, producing fragments similar to those cleaved by skin interstitial fluid, but different from those generated by plasmin. Protease inhibitor profiles suggested the enzyme in the conditioned medium to be a calcium-dependent serine protease.
Exogenous IGFBP-3 either inhibited or slightly stimulated IGF-I-induced cell proliferation when it was coincubated or preincubated with the cells, respectively. Both effects were attenuated in the presence of plasminogen.
Preincubation of cells with IGF-I or long R3 IGF-I divergently changed plasminogen activator inhibitor-1 and -2 secretion, but only IGF-I blocked IGFBP-3 proteolysis. Such inhibition was also observed in a cell-free protease assay. IGF-I, however, had no effect on plasmin-induced IGFBP-3 degradation.
Together, these data indicate that an IGFBP-3 protease similar to that in skin interstitial fluid is generated in plasminogen-treated HaCaT cells, and it attenuates the effects of IGFBP-3 on IGF action. IGF-I, probably by coupling with IGFBP-3, can protect it from the action of this protease.
This article has been cited by other articles:
![]() |
S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shalamanova, B. Kubler, J.-G. Scharf, and T. Braulke MDCK cells secrete neutral proteases cleaving insulin-like growth factor-binding protein-2 to -6 Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1221 - E1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Marinaro, E. C. Hendrich, K. S. Leeding, and L. A. Bach HaCaT human keratinocytes express IGF-II, IGFBP-6, and an acid-activated protease with activity against IGFBP-6 Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E536 - E542. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Shi, W. Xu, F. Loechel, U. M. Wewer, and L. J. Murphy ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., June 9, 2000; 275(24): 18574 - 18580. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |